Bluejay Diagnostics, Inc. — fact timeline

Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm for the fiscal year ending December 31, 2026. at the 2026-06-09 meeting.

“Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results for the proposal were as follows: Votes For Votes Against Abstentions 389,052 21,067 3,973”

Bluejay Diagnostics, Inc. shareholders approved Approve and adopt an amendment to the Company’s stock plan to increase the number of shares available for issuance thereunder from 61 shares to 600,061 shares. at the 2026-06-09 meeting.

“Proposal 3. Approve and adopt an amendment to the Company’s stock plan to increase the number of shares available for issuance thereunder - The Company’s stockholders approved and adopted the Plan Amendment to increase the number of shares of common stock issuable under the Stock Plan by 600,000 (from 61 shares to 600,061 shares). The voting results for the proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 135,750 94,058 1,160 183,124”

Bluejay Diagnostics, Inc. shareholders approved Election of Directors - Re-election of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve until the 2027 annual meeting. at the 2026-06-09 meeting.

“Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Douglas Wurth and Fred Zeidman to serve as directors until the Company’s 2027 annual meeting of stockholders, or until their successors are duly elected and qualified. The voting results for the proposal were as follows: Director Name Votes For Votes Withheld Broker Non-Votes Donald Chase 207,410 23,558 183,124 Neil Dey 207,842 23,126 183,124 Svetlana Dey 207,327 23,641 183,124 Douglas Wurth 207,337 23,631 183,124 Fred Zeidman 207,334 23,634 183,124”

Bluejay Diagnostics, Inc. issued Placement Agent Warrants to purchase up to an aggregate of 255,915 shares of common stock of warrant to H.C. Wainwright & Co. for services as placement agent.

“the Company issued to the placement agent (or its designees) warrants ("Placement Agent Warrants"”

Bluejay Diagnostics, Inc. issued pre-funded warrants to purchase up to 3,655,917 shares; Series G warrants to purchase up to 3,655,917 shares; Series H warrants to purchase up to 3,655,917 shar of warrant to institutional accredited investors for $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant.

“and (iii) Series H warrants (the “Series H Warrants”) to purchase up to 3,655,917 shares of common stock. The combined price of securities sold in the private placement was $2.324 per Pre-Funded Warrant and accompanying Series G Warrant and Series H Warrant. The Pre-Funded Warrants are immediately exercisable for shares of common stock at an exercise price”

Bluejay Diagnostics, Inc. entered into registration rights agreement with certain institutional, accredited investors (effective 2026-06-02).

“On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).”

Bluejay Diagnostics, Inc. entered into securities purchase agreement with certain institutional, accredited investors valued at approximately $7.7 million (effective 2026-06-02).

“On June 2, 2026, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement (the “private placement”).”

Bluejay Diagnostics, Inc. entered into Agreement and Statement of Work with Argonaut Manufacturing Services with Argonaut Manufacturing Services c/o Argonaut, Inc. valued at Provision of manufacturing services for the Company’s SymphonyTM platform, including planning, engin (effective 2026-05-27).

“On May 27, 2026, Bluejay Diagnostics, Inc. (the “Company”) entered into an agreement and statement of work (together, the “Agreement”) with Argonaut Manufacturing Services c/o Argonaut, Inc. (“Argonaut”) regarding the provision by Argonaut to the Company of certain manufacturing services to support the Company’s SymphonyTM platform.”

Bluejay Diagnostics, Inc. reported fiscal quarter ended March 31, 2026 results: net income approximately $1.9 million.

“As of March 31, 2026, Bluejay reported cash and cash equivalents of approximately $3.7 million. The Company reported a net loss of approximately $1.9 million for the first quarter of 2026, compared to approximately $1.9 million for the same period in 2025.”

Bluejay Diagnostics, Inc. entered into Agreement with the purchasers named therein valued at $125,000 (effective 2024-03-14).

“On March 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement (the “Agreement”)”

Bluejay Diagnostics, Inc. reported the fiscal year ended December 31, 2025 results: net income net losses of approximately $6.8 million.

“The Company expects to report $5.2 million in cash and cash equivalents and $6.0 million in stockholders’ equity as of December 31, 2025, following successful completion of a $3.8 million warrant-inducement financing in April 2025 and an additional $4.5 million PIPE financing in October 2025. The Company incurred net losses of approximately $6.8 million for the fiscal year ended December 31, 2025.”

Bluejay Diagnostics, Inc.: Amended charter to implement a 1-for-4 reverse stock split, effective January 29, 2026 (effective 2026-01-29).

“On January 27, 2026, the Company filed a certificate of amendment to the Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement a 1-for-4 reverse split of the Company’s common stock”

Bluejay Diagnostics, Inc. issued Placement Agent Warrants to purchase up to an aggregate of 180,000 shares of common stock of warrant to Rodman and Renshaw LLC (placement agent) for 125% of the combined price per share.

“the “common warrants”) to purchase up to an aggregate of 180,000 shares of common stock on the same terms as the Series F Warrants, except that the exercise price per share is 125% of the combined price per share and Series F Warrants sold in the offering. Pursuant to the terms of the registration rights agreement, the Company has agreed to register for”

Bluejay Diagnostics, Inc. issued Series F Warrants to purchase up to 4,500,000 shares of common stock of warrant to institutional, accredited investors for $2.00 per share.

“and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of”

Bluejay Diagnostics, Inc. issued Pre-Funded Warrants to purchase up to 2,075,000 shares of common stock of warrant to institutional, accredited investors for $2.00 per share.

“and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of”

Bluejay Diagnostics, Inc. issued 175,000 shares of common stock to institutional, accredited investors for $2.00 per share.

“and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of”

Jason Cook departed as Chief Technology Officer at Bluejay Diagnostics, Inc..

“Under the terms of the Separation Agreement, Dr. Cook will cease employment with the Company on May 30, 2025.”

Bluejay Diagnostics, Inc.: Amendment to Charter to implement a 1-for-50 reverse stock split (effective 2024-11-18).

“On November 15, 2024, the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement a 1-for-50 reverse split of its common stock (the “Reverse Stock Split”).”

Bluejay Diagnostics, Inc.: Reduced quorum requirement for stockholder meetings from a majority to one-third of shares entitled to vote (effective 2024-10-16).

“On October 16, 2024, the Board of Directors (the “Board”) of Bluejay Diagnostics, Inc. (the “Company”) approved Amendment No. 1 to the Amended and Restated Bylaws of the Company for the purpose of reducing the threshold required to establish a quorum for its meetings of stockholders from a majority of shares entitled to vote at such meetings to one-third of the shares entitled to vote at such meetings.”

Bluejay Diagnostics, Inc.: Increased authorized common shares from 7,500,000 to 50,000,000 via amendment to certificate of incorporation (effective 2024-05-14).

“On May 14, 2024, Bluejay Diagnostics, Inc. (the “Company”) filed an amendment to its amended and restated certificate of incorporation, which amendment increased the number of authorized shares of the Company’s common stock from 7,500,000 to 50,000,000.”

Bluejay Diagnostics, Inc. shareholders approved Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm at the 2024-05-14 meeting.

“Proposal 4. Ratification of Wolf & Company, P.C. as the Company’s Independent Registered Public Accounting Firm - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.”

Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split at the 2024-05-14 meeting.

“Proposal 3. Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to effect a reverse stock split of all of the Company’s outstanding shares of common stock by one of several fixed ratios between 1-for-2 and 1-for-10 (the “Reverse Stock Split”), with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined in the future by the Company’s board of directors, in its sole discretion and without further action by the Company’s stockholders.”

Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock at the 2024-05-14 meeting.

“Proposal 2. Approval of an Amendment to the Company’s Certificate of Incorporation to Increase the Number of Authorized Shares of Common Stock - The Company’s stockholders approved and adopted an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of the Company’s common stock.”

Bluejay Diagnostics, Inc. shareholders approved Election of directors at the 2024-05-14 meeting.

“Proposal 1. Election of Directors - The Company’s stockholders re-elected each of Donald Chase, Neil Dey, Svetlana Dey, Fred Zeidman, Gary Gemignani and Douglas Wurth to serve as directors until the 2025 Annual Meeting of Stockholders, or until their successors are duly elected and qualified.”

Neil Dey changed role as President and Chief Executive Officer (designated as principal financial and accounting officer) at Bluejay Diagnostics, Inc..

“the Board of Directors of the Company (the “Board”) has designated Neil Dey, the Company’s President and Chief Executive Officer, as the Company’s the principal financial and accounting officer, in addition to serving as principal executive officer.”

Frances Scally departed as Interim Chief Financial Officer at Bluejay Diagnostics, Inc..

“Frances Scally, who had served as the Company’s Interim Chief Financial Officer pursuant to such agreements with DLA, ceased serving as an officer of the Company.”

Bluejay Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 28, 2024, Bluejay Diagnostics, Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Capital”

Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional investors (effective 2023-12-27).

“On December 27, 2023, Bluejay Diagnostics, Inc. (the “Company”) commenced a public offering (such transaction, the “Offering”) for the issuance and sale of (i) 537,768 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and (ii) prefunded warrants to purchase up to an aggregate 2,154,540 shares of Common Stock (the “Prefunded Warrants”). The Shares and Prefunded Warrants were sold together with warrants to purchase up to an aggregate of 2,692,308 shares of Common Stock at an exercise price of $1.30 per share (the “Warrants”). Certain institutional investors purchasing securities as part of the offering entered into a securities purchase agreement with the Company (the “Purchase Agreement”), dated as of December 27, 2023.”

Bluejay Diagnostics, Inc. reported the three and nine months ended September 30, 2023 results: net income $2.29 million and $7.65 million, EPS $2.08 and $7.30 per share.

“the net loss for the three and nine months ended September 30, 2023 was $2.29 million and $7.65 million, or $2.08 and $7.30 per share, respectively”

Bluejay Diagnostics, Inc. amended New Toray Supply Agreement with Toray Industries, Inc. valued at Toray to manufacture near-term product intermediary components for FDA approval, not commercial sale (effective 2023-10-23).

“On October 23, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Toray Industries, Inc. (“Toray”) entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”).”

Bluejay Diagnostics, Inc. amended New Toray License Agreement with Toray Industries, Inc. valued at royalty reduced from 15% to 7.5% of net sales (effective 2023-10-23).

“On October 23, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Toray Industries, Inc. (“Toray”) entered into an Amended and Restated License Agreement (the “New Toray License Agreement”) and a Master Supply Agreement (the “New Toray Supply Agreement”).”

Kenneth R. Fisher departed as other_named_officer at Bluejay Diagnostics, Inc..

“On October 14, 2023, a Separation Agreement entered into between Bluejay Diagnostics, Inc. and Kenneth R. Fisher became effective and irrevocable in connection with Mr. Fisher’s prior separation from employment on September 26, 2023.”

Scott Levy was appointed as special advisor to the CEO at Bluejay Diagnostics, Inc..

“Under the these agreements, Scott Levy will complement Ms. Scally as a special advisor to the Company’s CEO.”

Frances Scally was appointed as Chief Financial Officer at Bluejay Diagnostics, Inc..

“On September 26, 2023, the Board of Directors (the “Board”) of the Company appointed Frances Scally, age 56, as interim CFO of the Company and designated her as the Company’s principal financial officer and principal accounting officer, effective immediately.”

Kenneth R. Fisher departed as Chief Financial Officer at Bluejay Diagnostics, Inc..

“On September 26, 2023, Bluejay Diagnostics, Inc. (the “Company”) and Kenneth R. Fisher agreed that Mr. Fisher would depart the Company as an employee and cease serving as its Chief Financial Officer (“CFO”).”

Bluejay Diagnostics, Inc. entered into Purchase Agreement with certain institutional and accredited investors valued at approximately $1.59 million (effective 2023-08-24).

“On August 24, 2023, Bluejay Diagnostics, Inc. (the “Company”) entered into a securities purchase agreement with certain institutional and accredited investors (the “Purchase Agreement”) relating to the registered direct offering and sale of 216,000 shares of the Company’s common stock”

Bluejay Diagnostics, Inc. reported the six months ended June 30, 2023 results: net income $5.4 million, EPS $5.24 per share.

“The net loss for the six months ended June 30, 2023 was $5.4 million, or $5.24 per share”

Bluejay Diagnostics, Inc.: Amended certificate of incorporation to implement a 1-for-20 reverse stock split and reduce authorized shares from 100,000,000 to 7,500,000 (effective 2023-07-24).

“At the Annual Meeting of Stockholders of Bluejay Diagnostics, Inc. (the “Company”) held on June 14, 2023 (the “Annual Meeting”), the stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to implement a reverse stock split of the Company’s common stock, par value $0.0001 per share, with the ratio to be determined by the Board of Directors (the “Board”) of the Company, at ratios of 1-for-5, 1-for-10, 1-for-20 or 1-for-25, respectively, and reduce the number of authorized shares of Common Stock under the Charter from 100,000,000 shares to 30,000,000, 15,000,000, 7,500,000 and 6,000,000 respectively. Thereafter, on July 21, 2023, the Company filed a certificate of amendment to its Charter (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, to implement the 1-for-20 reverse split of its common stock (the “Reverse Stock Split”) and to reduce the number of authorized shares of com”

Bluejay Diagnostics, Inc. shareholders approved Ratify Wolf & Company, P.C. as Independent Registered Public Accountant at the 2023-06-14 meeting.

“Proposal 3. Ratify Wolf & Company, P.C. as Independent Registered Public Accountant - The Company’s stockholders ratified the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, by the following vote:”

Bluejay Diagnostics, Inc. shareholders approved Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split at the 2023-06-14 meeting.

“Proposal 2. Approval of an Amendment to the Company’s Certificate of Incorporation to Effect a Reverse Stock Split - The Company’s stockholders approved the adoption of an Amendment to the Company’s Certificate of Incorporation to effect a reverse stock split of the Company’s common stock and adjust the number of shares authorized by the following vote:”

Bluejay Diagnostics, Inc. shareholders approved Election of Directors at the 2023-06-14 meeting.

“Proposal 1. Election of Directors - The Company’s stockholders elected Douglas Wurth, Neil Dey, Svetlana Dey, Donald Chase, Fred Zeidman and Gary Gemignani to serve until the 2024 Annual Meeting of Stockholders, or until their successors are duly elected and qualified.”

Bluejay Diagnostics, Inc. reported quarter ended March 31, 2023 results: net income $2.5 million, or $0.12 per share, EPS $0.12 per share.

“The net loss was $2.5 million, or $0.12 per share for the three months ended March 31, 2023, compared to $2.0 million, or $0.10 per share, for the comparable period in 2022.”

Bluejay Diagnostics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“April 25, 2023, Nasdaq’s Listing Qualifications Staff notified the Company that it has extended the time period for the Company to regain compliance with the Minimum Bid Requirement until October 23, 2023. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 or higher for a minimum of ten consecutive business days. The Company intends to continue to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Requirement. Specifically, the Company has confirmed to Nasdaq that”

Bluejay Diagnostics, Inc. reported the year ended December 31, 2022 results: net income $9.3 million, or $0.46 per share, EPS $0.46 per share.

“Bluejay Diagnostics Reports 2022 Financial Results”

Bluejay Diagnostics, Inc. reported nine months ended September 30, 2022 results: net income $6.9 million, EPS $0.34 per share.

“The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively”

Bluejay Diagnostics, Inc. reported quarter ended September 30, 2022 results: net income $3.0 million, EPS $0.15 per share.

“The net loss for the three and nine months ended September 30, 2022 was $3.0 million and $6.9 million, or $0.15 and $0.34 per share, respectively”

Bluejay Diagnostics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“October 25, 2022, Bluejay Diagnostics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Staff of The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that the closing bid price for its common stock had been below $1.00 for the previous 30 consecutive business days and that the Company therefore is not in compliance with the minimum bid price requirement for continued inclusion on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on The Nasdaq Cap”

Gordon Kinder resigned as Chief Financial Officer at Bluejay Diagnostics, Inc..

“on March 23, 2022, Bluejay Diagnostics, Inc. (the “Company”) accepted the resignation of Mr. Gordon Kinder from his position as Chief Financial Officer effective immediately.”

Gordon Kinder resigned as Chief Financial Officer at Bluejay Diagnostics, Inc..

“On March 23, 2022, the Company accepted the resignation of Mr. Gordon Kinder from his position as Chief Financial Officer effective immediately.”

Kenneth Fisher was appointed as Chief Financial Officer at Bluejay Diagnostics, Inc..

“On March 23, 2022, Bluejay Diagnostics, Inc. (the “Company”) entered into an employment agreement with Mr. Kenneth Fisher pursuant to which Mr. Fisher agreed to serve as Chief Financial Officer of the Company commencing on such date.”